Shares of ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF – Get Rating) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $4.83 and last traded at $4.78, with a volume of 3250 shares. The stock had previously closed at $4.98.
ProMIS Neurosciences Stock Performance
The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -442.00 and a beta of 1.08. The firm has a fifty day simple moving average of $5.56 and a 200 day simple moving average of $5.57. The company has a debt-to-equity ratio of 1.08, a current ratio of 10.37 and a quick ratio of 10.37.
About ProMIS Neurosciences
(Get Rating)
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (ARFXF)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
周三午盘,PROMIS神经科学公司(OTCMKTS:ARFXF-GET Rating)的股价创下52周新高。该公司盘中一度高见4.83美元,最新报4.78美元,成交量为3,250股。该股此前收盘价为4.98美元。
PROMIS神经科学类股表现
该公司市值19.1亿美元,市盈率为-442.00,贝塔系数为1.08.该公司的50日简单移动均线为5.56美元,200日简单移动均线为5.57美元。该公司的债务权益比为1.08,流动比率为10.37,速动比率为10.37。
关于PROMIS神经科学
(获取评级)
Promis神经科学公司发现和开发用于治疗神经退行性疾病的精确医学解决方案,主要是加拿大的阿尔茨海默病(AD)、肌萎缩侧索硬化症(ALS)和多系统萎缩(MSA)。该公司的专有发现平台包括PROMIS和Collective坐标算法,用于预测错误折叠蛋白质分子表面上被称为疾病特异性表位的新靶点。
推荐故事
- 免费获取StockNews.com关于Promis神经科学的研究报告(ARFXF)
- 金塔拉治疗公司是一颗隐藏的宝石吗?
- 你应该热身到Generac股票过冬吗?
- 长期持有的3只高收益股利股票
- 加州缅因州公布创纪录的季度业绩,保持冷静的收入投资者
- 特斯拉股票:公牛和熊队哪里出了问题
接受PROMIS神经科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Promis神经科学和相关公司的最新新闻和分析师评级的每日简要摘要。